Rating Rationale
April 07, 2022 | Mumbai
Gufic Biosciences Limited
Rating outlook revised to 'Positive'; Ratings reaffirmed; Rated amount enhanced
 
Rating Action
Total Bank Loan Facilities RatedRs.145 Crore (Enhanced from Rs.20 Crore)
Long Term RatingCRISIL BBB+/Positive (Outlook revised from 'Stable'; Rating Reaffirmed)
Short Term RatingCRISIL A2 (Assigned)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has revised its outlook on the long-term bank facilities of Gufic Biosciences Limited (GBL) to 'Positive' from 'Stable', while reaffirming the rating at 'CRISIL BBB+'. and has assigned its 'CRISIL A2' rating to the short-term bank facility.

 

The outlook revision reflects improvement in GBL’s business risk profile in fiscal 2022, marked by expected revenue of Rs. 750 crore, increase from Rs 488 crores in fiscal 2021, driven by capacity expansion and higher revenue from critical drugs. Operating profitability improved in fiscal 2021 to 17.6% and expected to sustain in fiscal 2022. With further capacity expansion in FY2023, revenue is expected to grow in future years.  Hence, sustenance of operating margin and revenue growth will remain key rating sensitivity factors. Financial profile and liquidity continue to be strong.

 

The ratings reflect established market position of GBL in the pharmaceutical business, well-established customer base, and comfortable financial risk profile. These strengths are partially offset by vulnerability to adverse changes in government regulations, large working capital requirement, and exposure to risks related to the ongoing project.

Key Rating Drivers & Detailed Description

Strengths:

  • Established market position in the pharmaceutical industry

The promoters have over five decades of experience in the pharmaceutical industry; their strong understanding of market dynamics and healthy relations with customers and suppliers should continue to support the business. GBL obtained various certifications and approvals for its manufacturing facilities and diversified its product portfolio through continuous research and development. The top 10 products contributed to 34% of revenue till the third quarter of fiscal 2022. Revenue grew to an estimated Rs 750 crore in fiscal 2022 from Rs 300 crore in fiscal 2018.

 

  • Well-established customer base

Clientele comprises large players such as Glenmark Pharmaceuticals Ltd, Lupin Ltd, Abbott Healthcare Pvt Ltd and Zydus Healthcare Ltd. Healthy relationship with reputed pharmaceutical players led to repeat orders, contributing to steady revenue growth over the years. Besides, it has a network of 25 carrying & forwarding agents and more than 500 stockists PAN India through which it has access to over 1 lakh retailers. The top 10 customers contribute 30-35% to the revenue profile. Benefits from longstanding relation with the well-established customer base will persist.

 

  • Comfortable financial risk profile

Financial risk should remain strong despite the huge, debt-funded capex to be undertaken in fiscal 2023. Networth was Rs 173 crore as on March 31, 2021 and is estimated at Rs 250 crore on March 31, 2022. Its controlled reliance on external debt has led to comfortable gearing and total outside liabilities to adjusted networth (TOLANW) ratios, which are estimated to be 0.14-0.15 times and 0.8-0.9 times, respectively in fiscal 2022. Debt protection metrics are robust, with interest coverage and net cash accrual to adjusted debt ratios estimated at 25 times and 2.5 times, respectively, for fiscal 2022.

 

Weaknesses:

  • Vulnerability to adverse changes in government regulations

The pharmaceutical industry is highly regulated by state governments and various government agencies, which approve new drugs and clinical trials, control the quality of imported drugs, and set prices for many critical drugs; while state authorities regulate manufacture, sales, and distribution. Any unfavourable regulation may adversely impact the business of GBL.

 

  • Large working capital requirement

The working capital cycle is likely to remain stretched. Gross current assets (GCAs) have been 190- 250 days over the past four fiscals ended March 31, 2021, with high debtors (90-110 days) and huge inventory (90-130 days). The company extends long credit period of 90-120 days to customers. Furthermore, due to its business need, it holds large raw material and work in process inventory of 90-120 days. GBL’s operations are expected to remain working capital intensive over the medium term.

 

  • Exposure to risks related to ongoing project

GBL has undertaken a greenfield project at Indore (Madhya Pradesh) to expand capacities of existing formulations/injectables and incorporate new product lines. It involves capital outlay of around Rs 225 crore (of which Rs 160 crore is funded by debt) and is expected to be completed by fiscal 2024 beginning. Timely completion of project, without any significant time and cost overrun, and subsequent ramp-up in operations will remain key monitorables.

Liquidity: Adequate

Cash accrual is projected at over Rs 90-100 crore per annum for fiscals 2023 and 2024, sufficient to meet the yearly repayment obligation of Rs 4.5-5.0 crore. The fund-based bank limit of Rs 90 crore was sparsely utilised during the 12 months through February 2022. Cash and cash equivalents were Rs 13.1 crore as on March 31, 2021. It has capex plans in fiscal 2023 of Rs. 250 crores, which will be funded through Rs. 160 crore of debt and remaining through accruals. CRISIL Ratings expects internal accruals, cash and cash equivalents and unutilized bank lines to be sufficient to meet its capex, repayment obligations and incremental working capital requirements.

Outlook: Positive

CRISIL Ratings believe GBL’s business risk profile will continue to improve over the medium term, driven by increasing scale of operations while sustaining operating margin; while financial profile will remain strong despite capex

Rating Sensitivity factors

Upward factors

  • Sustained revenue growth and sustenance of operating margin above 18%, leading to higher cash accruals
  • Improvement in working capital cycle with GCA below 160 days, strengthening its financial risk profile

 

Downward factors

  • Sharp decline in revenue or operating margin below 15%, leading to lower-than-expected cash accruals
  • Stretch in working capital requirements, or higher than expected capex, weakening its liquidity

About the Company

GBL, incorporated in 1984, by the Choksi family, manufactures formulations across various therapeutic segments such as antifungal, anesthetics, and immunosuppressants. The key business segments are pharmaceutical products (75% revenue), bulk drugs (15%) and consumer care products (10%). Its facilities are at Navsari, Baroda in Gujarat, Belgaum in Karnataka and Indore. Mr Jayesh P Choksi (chairman and managing director) and Mr Pranav J Choksi (CEO) manage the business. GBL is listed on Bombay Stock Exchange and National Stock Exchange.

Key Financial Indicators

As on / for the period ended March 31

 

2021

2020

Operating income

Rs crore

488.17

379.11

Reported profit after tax (PAT)

Rs crore

44.23

22.69

PAT margin

%

9.06

5.98

Adjusted debt/adjusted networth

Times

0.32

0.91

Interest coverage

Times

6.43

3.92

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon
rate (%)

Maturity

date

Issue size
(Rs crore)

Complexity

level

Rating assigned

with outlook

NA

Cash credit

NA

NA

NA

20

NA

CRISIL BBB+/Positive

NA

Cash credit

NA

NA

NA

62

NA

CRISIL BBB+/Positive

NA

Term loan

NA

NA

Mar-31

37

NA

CRISIL BBB+/Positive

NA

Letter of credit

NA

NA

NA

26

NA

CRISIL A2

 

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 119.0 CRISIL BBB+/Positive   -- 25-10-21 CRISIL BBB+/Stable   --   -- --
Non-Fund Based Facilities ST 26.0 CRISIL A2   --   --   --   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit 20 Axis Bank Limited CRISIL BBB+/Positive
Cash Credit 62 The Saraswat Co-Operative Bank Limited CRISIL BBB+/Positive
Letter of Credit 26 Axis Bank Limited CRISIL A2
Long Term Loan 37 The Saraswat Co-Operative Bank Limited CRISIL BBB+/Positive

This Annexure has been updated on 07-Apr-22 in line with the lender-wise facility details as on 21-Oct-21 received from the rated entity,

Criteria Details
Links to related criteria
Rating Criteria for the Pharmaceutical Industry
The Rating Process
CRISILs Bank Loan Ratings
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
CRISILs Bank Loan Ratings
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Pankaj Rawat
Media Relations
CRISIL Limited
B: +91 22 3342 3000
pankaj.rawat@crisil.com

Hiral Jani Vasani
Media Relations
CRISIL Limited
B: +91 22 3342 3000
hiral.vasani@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Prashant Soodamani
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Prashant.Soodamani@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html